These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

As of December 31, 2024, Fortress’ consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as of September 30, 2024, and $80.9 million as of December 31, 2023, a ...

This comprehensive list highlights the 100 most influential biotech leaders who are shaping the future of the industry. From startup founders to corporate executives, these individuals represent the ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings ... with two global pharmaceutical companies for our lead proprietary compound, LB-100, to treat ovarian and colorectal ...

Study published in EMBO, highlighting how LB-100 forces cancer cells to create neo antigens and make them more vulnerable for immunotherapy. About LIXTE Biotechnology Holdings, Inc. LIXTE ...

PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings ... companies for our lead proprietary compound, LB-100, to treat ovarian and colorectal cancer,” said Bas ...

Artificial intelligence (AI) has taken the biotech industry by storm ... This funding took the total raised by the company to date to more than $100 million. Based in Paris, Iktos is making use of AI ...

Antibiotics for pneumonia include Zithromax (azithromycin), Biaxin (clarithromycin), and Erythrocin (erythromycin). Azithromycin is often the first-line treatment since it is effective against many ...

We believe that Emrosi will become a major growth driver for Journey Medical, given its potential to achieve peak annual sales of an estimated $200 million in the United States, and $100 million ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Fortress Biotech Stock Performance Fortress Biotech stock opened at $1.72 on Thursday. The company has a market capitalization of $47.48 million, a P/E ratio of -0.56 and a beta of 1.75.